Literature DB >> 16926960

Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations.

Nina Boucher1, Louise Beaulac-Baillargeon.   

Abstract

OBJECTIVE: To assess whether prescribing physicians advised female patients taking isotretinoin according to pregnancy prevention recommendations, whether women understood those recommendations, and whether women complied with recommendations to prevent pregnancy.
DESIGN: Cross-sectional study designed to collect patients' self-reported information. Women were interviewed by telephone with a standardized questionnaire.
SETTING: Quebec. PARTICIPANTS: Participants were recruited through pharmacies, medical clinics, and newspapers in Quebec. All subjects (45 women 14 years and older) were treated with isotretinoin at the time of the interview or in the preceding 6 months. MAIN OUTCOME MEASURES: Women's self-report of their physician's behaviour regarding prevention of pregnancy, women's comprehension of the information, and their level of compliance with recommendations.
RESULTS: Prescribing physicians discussed the risks of teratogenesis with 93% of the women but gave written information to only 36% of them. Seventy-eight percent of the women admitted not using 2 contraceptive methods all the time during the treatment, and 3 women reported having had sexual intercourse without any contraception. Physicians prescribed a pregnancy test before treatment for 44% of the women. Only 18% of the women waited for their next menstrual period to begin isotretinoin treatment, and this advice was given by 20% of physicians. A statistically significant relationship between counseling and recommendations given by physicians and women's use of double contraception was highlighted.
CONCLUSION: Female patients reported physicians did not always advise them according to recommendations concerning pregnancy prevention. Women understood the information received but did not fully comply. The extent of pregnancy prevention measures taken by physicians was linked to women's compliance. Further study exploring underlying reasons for women's noncompliance could provide information on changing such behaviour.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926960      PMCID: PMC1479707     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  18 in total

1.  Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program.

Authors:  G Atanackovic; G Koren
Journal:  CMAJ       Date:  1999-06-15       Impact factor: 8.262

Review 2.  How to ensure fetal safety when mothers use isotretinoin (Accutane).

Authors:  G Koren; A Pastuszak
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

3.  Unintended pregnancy in the United States.

Authors:  S K Henshaw
Journal:  Fam Plann Perspect       Date:  1998 Jan-Feb

4.  Oral retinoids. Broad-spectrum dermatologic therapy for the 1980s.

Authors:  J J Voorhees; C E Orfanos
Journal:  Arch Dermatol       Date:  1981-07

5.  Accutane Roche: risk of teratogenic effects.

Authors:  D P Zarowny
Journal:  Can Med Assoc J       Date:  1984-08-15       Impact factor: 8.262

6.  Use of the Retinoid Pregnancy Prevention Program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate.

Authors:  A Pastuszak; G Koren; M J Rieder
Journal:  Reprod Toxicol       Date:  1994 Jan-Feb       Impact factor: 3.143

7.  Teratogenic effects of retinoic acid in pigtail monkeys (Macaca nemestrina). II. Craniofacial features.

Authors:  L Newell-Morris; J E Sirianni; T H Shepard; A G Fantel; B C Moffett
Journal:  Teratology       Date:  1980-08

8.  Retinoic acid embryopathy.

Authors:  E J Lammer; D T Chen; R M Hoar; N D Agnish; P J Benke; J T Braun; C J Curry; P M Fernhoff; A W Grix; I T Lott
Journal:  N Engl J Med       Date:  1985-10-03       Impact factor: 91.245

9.  [Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines].

Authors:  E Autret; M Radal; A P Jonville-Béra; J M Goehrs
Journal:  Ann Dermatol Venereol       Date:  1997       Impact factor: 0.777

10.  A pregnancy-prevention program in women of childbearing age receiving isotretinoin.

Authors:  A A Mitchell; C M Van Bennekom; C Louik
Journal:  N Engl J Med       Date:  1995-07-13       Impact factor: 91.245

View more
  7 in total

Review 1.  Pregnancy and isotretinoin therapy.

Authors:  June Seek Choi; Gideon Koren; Irena Nulman
Journal:  CMAJ       Date:  2013-01-07       Impact factor: 8.262

2.  Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France.

Authors:  Elisabeth Autret-Leca; Carmen Kreft-Jais; Elisabeth Elefant; Hawaré Cissoko; François Darrouzain; Lamiae Grimaldi-Bensouda; Sarah Attia; Annie Pierre Jonville-Béra
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

3.  Patients' Knowledge and Information Needs about Isotretinoin Therapy Use in Jordan.

Authors:  Anan S Jarab; Sayer Al-Azzam; Shriefa Almutairi; Tareq L Mukattash
Journal:  Int J Clin Pract       Date:  2022-02-14       Impact factor: 3.149

4.  Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy.

Authors:  David Henry; Colin Dormuth; Brandace Winquist; Greg Carney; Shawn Bugden; Gary Teare; Linda E Lévesque; Anick Bérard; J Michael Paterson; Robert W Platt
Journal:  CMAJ       Date:  2016-04-25       Impact factor: 8.262

5.  Washout Period for Pregnancy Post Isotretinoin Therapy.

Authors:  Hina Jajoria; Venkataram Mysore
Journal:  Indian Dermatol Online J       Date:  2020-03-09

6.  Proper Counseling and Dispensing of Isotretinoin Capsule Products by Community Pharmacists in UAE: A Simulated Patient Study.

Authors:  Zainab A Rashid; Moawia M Al-Tabakha; Muaed Jamal Alomar
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-06-16

Review 7.  Drug safety: The concept, inception and its importance in patients' health.

Authors:  Thamir M Alshammari
Journal:  Saudi Pharm J       Date:  2014-05-09       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.